Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15586456 | 0.85 | HTR2A (0.42) | HTR2CHTR2APOLLABCB1CA12 | |
| SCHEMBL16577518 | 0.73 | ABCB1 (0.57) | HTR2CHTR2APOLLDRD2ABCB1 | |
| SCHEMBL9870482 | 0.71 | ABCB1 (0.64) | HTR2CHTR2ADRD2ABCB1CA12 | |
| SCHEMBL15586457 | 0.70 | ABCB1 (0.50) | HTR2CHTR2APOLLDRD2ABCB1 | |
| SCHEMBL17401223 | 0.70 | HTR2A (0.47) | HTR2CHTR2APOLLMEN1KMT2A | |
| SCHEMBL17401224 | 0.70 | HTR2A (0.47) | HTR2CHTR2APOLLMEN1KMT2A | |
| SCHEMBL1515163 | 0.70 | HTR2C (0.75) | HTR2CDRD2MEN1KMT2ACA12 | |
| SCHEMBL27425024 | 0.69 | KDM4E (0.44) | HTR2CHTR2APOLLMEN1KMT2A | |
| SCHEMBL29987588 | 0.69 | HTR2C (0.49) | HTR2CHTR2ADRD2MEN1KMT2A | |
| SCHEMBL16398448 | 0.69 | HTR2C (0.53) | HTR2CHTR2ADRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| EP-1517882-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1084109-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PROD INC (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004000789-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1084109-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | Pfizer Products Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062883-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SLC10A1, HAVCR2, UGT1A3 | HTR2C 3516/4885HTR2A 4676/4885POLL 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.